{
  "abstract": "Background and Aims Antifibrotic treatments for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PFILD) have several side effects which can limit patients‘ ability to continue treatment. A previous service evaluation at our Tertiary ILD centre identified gastrointestinal (GI) side effects and deranged liver function tests (LFTs) as the main causes of patients permanently stopping medication. Due to this we developed an Antifibrotic Side-effect Decision Aid for use by all team members to help identify severity, standardise advice and guide management of common side effects, including pages for diarrhoea, nausea and abnormal LFTs. The Decision Aids were presented at local and regional meetings from August 2023 and approved by local clinical governance committees prior to deployment in May 2024. We aimed to review the impact of the Decision Aids on antifibrotic tolerance, and impact on clinical contacts outside our established antifibrotic pathway.Methods We reviewed 2 cohorts of consecutive patients who initiated antifibrotic medication at our Tertiary ILD centre, 50 pre-Decision Aid between May-July 2023 and 50 post-Decision Aid between July-October 2024. We reviewed medical records for 3 months after starting medication and identified any dose changes, reasons for changes, and patient outcomes at 3 months. We documented contacts to the specialist nurses outside our standard antifibrotic pathway via our telephone contact line. Chi-squared or Fishers exact tests were used as appropriate for group comparisons.Results There were no significant differences in antifibrotic used, initial dose, age or BMI between the pre and post-Decision Aid cohorts ( table 1). Fewer patients had treatment breaks for GI side effects in the post-Decision Aid cohort (p=0.038) with more patients increasing their dose (p=0.001). Fewer patients permanently stopped medication in the post-Decision Aid cohort (6% vs 24%, p=0.023). There was no increase in patient contacts outside the established antifibrotic pathway, with a higher proportion of patients not utilising the contact line within the first 3 months (p=0.004).Abstract P27 Table 1Discussion The Decision Aids have had a positive impact on patient tolerance and treatment continuation during the initial 3-month period without a significant increase in patient contacts to the specialist nurse contact line.",
  "authors": [
    {
      "affiliations": [
        "Leeds Teaching Hospitals Trust, Leeds, UK"
      ],
      "name": "J Bradley"
    },
    {
      "affiliations": [
        "Leeds Teaching Hospitals Trust, Leeds, UK"
      ],
      "name": "J Slough"
    },
    {
      "affiliations": [
        "Leeds Teaching Hospitals Trust, Leeds, UK"
      ],
      "name": "T Capstick"
    },
    {
      "affiliations": [
        "Leeds Teaching Hospitals Trust, Leeds, UK"
      ],
      "name": "A Boland"
    },
    {
      "affiliations": [
        "Leeds Teaching Hospitals Trust, Leeds, UK"
      ],
      "name": "TJT Sutherland"
    },
    {
      "affiliations": [
        "Leeds Teaching Hospitals Trust, Leeds, UK"
      ],
      "name": "P Beirne"
    }
  ],
  "title": "P27 Can antifibrotic side-effect decision aids improve patient tolerance and continuation of antifibrotic medication?",
  "uid": "77071502-6bee-50da-b142-0f26d55a8e6b"
}